Xarelto
FDA approves Janssen’s Xarelto for blood clot prevention
October 15, 2019Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
Bayer’s Xarelto combo greenlighted by NICE for reducing CV events in artery disease
August 1, 2019Sales and Marketing NHS, NICE, UK, Xarelto, cardiovascular disease, pharma
NICE has awarded final appraisal recommendation to Bayer’s Xarelto (rivaroxaban) at a dosage of 2.5mg twice daily in combination with …
J&J joins in on industry price hiking; almost 500 drug prices increased in 2019 so far
January 11, 2019Medical Communications, Sales and Marketing J&J, JJ, Stelara, US, Xarelto, Zytiga, pharma, price hikes
It’s only the second week of the New Year, and Johnson & Johnson has announced plans to hike the prices …
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
Bayer and J&J successfully reverse $28 million Xarelto court payout
January 10, 2018Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma
Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …
Bayer forced to halt huge study into key drug
October 6, 2017Medical Communications, Research and Development Bayer, Janssen, Xarelto, biotech, drugs, pharma, pharmaceutical
Bayer, and development partner Janssen, have been forced to stop a Phase 3 trial looking at expanding the indication of …
Bayer’s cardiovascular drug races to target in trial
February 9, 2017Research and Development, Sales and Marketing Bayer, Janssen, Xarelto
Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …
Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
September 29, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin
The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Bayer backs safety of Xarelto after real-world data study
September 2, 2015Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban
Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
Bayer promotes Xarelto benefits
June 15, 2015Sales and Marketing Bayer, Eliquis, Xarelto, blood, law suits, rivaroxaban
Bayer HealthCare is releasing new evidence to suggest that the risk of taking its best-selling blood thinner Xarelto is outweighed …
Chinese government to lift drug price controls
May 5, 2015Sales and Marketing China, Drug pricing, GSK, IMS, Xarelto, government
The Chinese government has announced that it will remove price caps for most medicines and allow the market to play …
Bayer buys blood-thinning drug from Isis
May 5, 2015Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning
German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …
Profits fall at Bayer but new drugs see growth
May 1, 2015Sales and Marketing Bayer, Eliquis, Eylea, Renegeron, Xarelto, apixaban
Bayer’s pharmaceutical revenues have continued their upward trajectory in the first quarter of 2015 thanks to new products, although this …
Latest content
FibroFind appoints Lee Borthwick as CEO
